SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Zydus Lifesciences’ Desidustat tablets secure approval for renal anaemia in China

16 Mar 2026 Evaluate

Zydus Lifesciences’ innovative drug ‘Desidustat tablets’, licensed to the subsidiary of China Medical System Holdings, has been approved for renal anaemia in China by the National Medical Products Administration of China (NMPA). CMS International Development and Management, a wholly-owned subsidiary of China Medical System Holdings (CMS) had obtained an exclusive license for the drug from the company in 2020. Desidustat is discovered, developed and marketed by the company in India under the brand name ‘Oxemia’. 

Desidustat tablets are administered orally and represent a novel, oral Hypoxia-Inducible Factor-Prolyl Hydroxylase Inhibitor (HIF-PHI) for treating anaemia in Chronic Kidney Disease (CKD) patients. CKD involves the gradual loss of kidney function and eventually leads to kidney failure. Healthy kidneys naturally secrete a hormone called Erythropoietin (EPO), which stimulates red blood cell production, also known as erythropoiesis. When kidneys are impaired in patients with Chronic Kidney Disease, EPO production is reduced, leading to the development of anaemia. HIF-PHI promotes erythropoiesis by increasing endogenous erythropoietin, reducing hepcidin thereby improving iron availability.

Zydus Lifesciences (formerly known as Cadila Healthcare), a company limited by shares, incorporated and domiciled in India, operates as an integrated pharmaceutical company with business encompassing the entire value chain in the research, development, production, marketing and distribution of pharmaceutical products.

Zydus Lifesciences Share Price

942.55 3.35 (0.36%)
17-Apr-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1675.20
Dr. Reddys Lab 1235.40
Cipla 1238.30
Zydus Lifesciences 942.55
Lupin 2324.25
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×